New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
10:15 EDTINSMInsmed drops, bounces, after Arikayce Phase 2 trial results
The stock is down over 10% at time of writing to $16.46 after Arikayce did not achieve the primary endpoint in Phase 2 trial. Shares hit a low of $15.69, currently support, and then bounced. Resistance is at the session high at $17.38. Piper Jaffray noted that the 'much more meaningful' secondary endpoint was met.
News For INSM From The Last 14 Days
Check below for free stories on INSM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for INSM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use